linjc16/ctgov huggingface dataset:
Role of Lung Function for Exercise Capacity in Well-trained Individuals

Study Overview
=================
Brief Summary
-----------------
The purpose of the project is to investigate exercise performance in humans following prolonged inhalation of beta2-agonists vilanterol + fluticasone furoate or indacaterol + mometasone furoate

Official Title
-----------------
Role of Lung Function, Airway Inflammation and Bronchial Hyper Reactivity for Exercise Capacity in Well-trained Individuals

Conditions
-----------------
Exercise Performance

Intervention / Treatment
-----------------
* Drug: Vilanterol and Fluticasone Furoate
* Drug: Indacaterol and Mometasone Furoate
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-39 Physically active > 5 h weekly Maximal oxygen consumption classified as high or very high Exclusion Criteria: Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid ECG abnormality ACQ score > 1.5 Severe bronchial hyperreactivity as determined by mannitol test FEV1/FVC ratio < 0.7 determined with spirometry Chronic illness determined to be a potential risk for participant during study In chronic treatment with medication that may interfere with study results Pregnancy Smoker Blood donation during the past 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vilanterol<br>Participants inhale vilanterol + fluticasone furoat | Drug: Vilanterol and Fluticasone Furoate<br>* Participants inhale 25 µg vilanterol + fluticasone furoate daily<br>|
| Experimental: Indacaterol<br>Participants inhale indacaterol + mometasone furoate | Drug: Indacaterol and Mometasone Furoate<br>* Participants inhale 125 µg indacaterol + mometasone furoate daily<br>|
| Placebo Comparator: Placebo<br>Participants inhale placebo | Drug: Placebo<br>* Participants inhale placebo daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise capacity during a time trial | Mean power output measured in Watts during a time trial on a bike ergometer | Through study completion, an average of 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung function | Forced expiratory volume in 1 second (FEV1) measured by spirometry before and after time trial with and without beta2-agonist induced bronchodilation | Through study completion, an average of 8 weeks |
Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver

Study Overview
=================
Brief Summary
-----------------
Radioembolization is an established treatment option for patients with unresectable primary and secondary liver tumors. Microspheres containing 90Y are injected intraarterially to deliver a high radiation dose to the tumors. Despite of our knowledge on the effectiveness of 90Y glass microspheres in the treatment of HCC, literature data on the treatment of metastatic colorectal cancer (mCRC) patients with 90Y glass microspheres is limited. In the recent EANM guideline variable healthy liver doses are recommended for patients with mCRC with an effective tumor dose recommendation based on a study with limited number of patients. Primary objectives; Investigate effective tumor dose and safe healthy liver dose in radioembolization for colorectal cancer liver metastasis using multicompartment dosimetry Secondary objectives; Investigate dose-response and dose-toxicity relationships, time to progress, concordance between pretreatment and posttreatment dose calculations.

Official Title
-----------------
Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver

Conditions
-----------------
Transarterial Radioembolization

Intervention / Treatment
-----------------
* Device: Therasphere


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 18 years old histopathologically proven colorectal cancer diagnosis treated with radioembolization for liver metastases with Y90 glass microspheres in lobar or segmental fashion have follow-up data at least 6 months after radioembolization Exclusion Criteria: no PET-CT, CT or MR of the liver within last 6 weeks prior to radioembolization. No PET-CT, CT or MR of the liver 2-4 months after radioembolization Poor image quality Previous local treatment or surgery for the liver

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observation group<br>Patients who received radioembolization for colorectal cancer liver metastases | Device: Therasphere<br>* Transarterial radioembolization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effective tumor dose and safe healthy liver dose | Compare the mean effective tumor doses effective tumour dose (in Gy) of patients with or without response to radioembolization for colorectal cancer liver metastasis. | 3th month after treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dose (in Gy) -response and dose (in Gy)-toxicity relationships | Investigate dose-response and dose-toxicity relationships after transarterial radioembolization. | 6th month after treatment |
Analysis of Oxidative Stress Biomarkers and Their Determinants in ART-experienced PLWH

Study Overview
=================
Brief Summary
-----------------
The project aims to assess the level of oxidative stress biomarkers in HIV patients on effective antiretroviral treatment in correlation with other therapeutic, clinical, and viro- immunological parameters. The analysis aims to better characterize the patient on treatment through an innovative approach based on two specific tests for complementary assessment of total oxidant and anti-oxidant plasma capacity.

Official Title
-----------------
Analysis of Oxidative Stress Biomarkers and Their Determinants in ART-experienced PLWH

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Other: blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ART-treated PLWH HIV-1 RNA< 50 copies/mL Stable ART therapy (at least 48 weeks) Signature of informed consent for study participation Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single arm<br>ART-experienced PLWH | Other: blood sampling<br>* Blood sampling for evaluation of oxidative stress markers<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the levels of total oxidant and antioxidant plasma capacity | Quantify the levels of total oxidant and antioxidant plasma capacity antioxidant | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between level of oxidative stress biomarkers and several factors | Evaluation of the impact of therapeutic, viro-immunologic, clinical, and demographic factors on the level of oxidative stress biomarkers. | 1 year |
Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the efficacy double trigger [ co-administration of GnRH agonist with HCG 40 and 34 h prior to ovum pick-up, respectively] with HCG trigger in inducing oocyte maturation.

Detailed Description
-----------------
Several studies revealed that the double trigger regimen was effective in the treatment of patients with a history of immature oocytes retrieved or with suboptimal oocytes yield. The investigators designed this randomized controlled trial to compare the efficacy double trigger with HCG trigger in inducing oocyte maturation.in normoreponders undergoing IVF-ET

Official Title
-----------------
Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger . A Randomized Controlled Trial

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: Double trigger
* Drug: HCG trigger


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normoresponders GnRH antagonist cycles Exclusion Criteria: BMI more than 35 Endometriosis AMH less than 1.1 ng AMH more than 4 PCOS Poor responders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Double trigger<br>GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before oocyte retrieval | Drug: Double trigger<br>* GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before ovum pick-up<br>* Other names: Augmented trigger;|
| Active Comparator: HCG trigger<br>HCG ( 100000 IU/ I.M ) is administered 36 h before oocyte retrieval | Drug: HCG trigger<br>* hCG ( 10000 IU) is administered 36 h before ovum pick-up<br>* Other names: Conventional trigger;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metaphase-II oocytes rate | Number of MII oocyte/ number of cumulus oocyte complex | Ten to fifteen days after starting ovarian stimulation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate | Presence of intrauterine gestational sac detected by transvaginal ultrasound | 5 weeks after embryo transfer | 
| Ongoing Pregnancy Rate | Pregnancies continued beyond 20 weeks gestation | 18 weeks after embryo transfer | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF-ET, Infertility, HCG trigger, Double trigger
Assessment of Bronchial Asthma Among Patients Attending Sohag University Hospital

Study Overview
=================
Brief Summary
-----------------
Asthma is a significant public health threat, affecting more than 300 million individuals globally. Asthma is classified as a non-communicable disease and leads to reduced quality of life, poor physical functioning and reduced emotional well-being. The impact of this disease can be widespread and extends beyond the person living with the disease, affecting the lives of their family members, carers, communities and the health care system (1). Asthma is a variable chronic respiratory condition. It is characterized by symptoms of wheeze, cough, chest tightness, dyspnea and backed by variable airflow limitation, airway inflammation and airway hyper-responsiveness (AHR). The severity of asthma varies considerably, both between individuals and within individuals over time. Some people may have intermittent asthma and others may experience severe, potentially life-threatening disease (2, 3,4).

Official Title
-----------------
Assessment of Bronchial Asthma Among Patients Attending Sohag University Hospital

Conditions
-----------------
Bronchial Asthma

Intervention / Treatment
-----------------
* Drug: corticosteroids


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: bronchial asthma patients aged more than 18 years, both sexes are included Exclusion Criteria: children ,patients who are unable to do spiromerty or contrindecated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group A,<br>group A (controlled bronchial asthma patients) | Drug: corticosteroids<br>* inhailed or oral corticosteroids<br>|
| group B<br>group B(uncontrolled bronchial asthma patients) | Drug: corticosteroids<br>* inhailed or oral corticosteroids<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percent of controlled bronchial asthma patients | to detect percent of controlled patients | 12 months |
Prevalence and Risk Factors of Helicobacter Pylori Infection in Children and Young Adults

Study Overview
=================
Brief Summary
-----------------
Helicobacter pylori is a gram-negative bacterium that resides in the stomach and can cause inflammation leading to long-term effects, such as gastric ulcers, cancer, and lymphoma of the stomach mucosal linings Previous research and analysis of H. pylori prevalence in populations have examined common risk factors that increase the likelihood of acquiring the bacteria. Some of the most commonly identified risk factors across various studies in different geographic populations are larger family size, less education, lower socioeconomic status, less frequent hygiene practices, and lower sanitation with specific emphasis on sources of water and defecation. aim of the work: Studying prevalence of Helicobacter Pylori infection and its related risk factors in children and young adults in Sohag governorate.

Official Title
-----------------
Prevalence and Risk Factors of Helicobacter Pylori Infection in Children and Young Adults in Sohag Governorate

Conditions
-----------------
Helicobacter Pylori Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children and young adults (between 2 to 25 years old) Exclusion Criteria: children below 2 years old adults more than 25 years old

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Studying prevalence of Helicobacter Pylori infection in children and young adults in Sohag governorate | determine the prevalence of Helicobacter Pylori infection in children and young adults in Sohag governorate by examining stool samples from 667 patients to detect h.pylori antigen | 12 weeks following the startpoint of the study. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| detecting risk factors related to Helicobacter Pylori infection in children and young adults in sohag governorate | We will use a semi-structured questionnaire to detect helicobacter pylori risk factors which include the following : Socio-demographic data, personal habits, physical activity and exercises, history of symptoms suggesting helicopter pylori infection like episodes of epigastric pain, vomiting and dyspepsia and family history, medication and comorbidities . | 12 weeks following the startpoint of the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Helicobacter pylori, dyspepsia, children, young adults, prevalence, peptic ulcer, risk factors
ScanNav Anatomy PNB FDA Data Collection Plan

Study Overview
=================
Brief Summary
-----------------
To gather additional training and/or validation data (recorded ultrasound scans) for ScanNav Anatomy PNB in the following categories: Femoral Nerve (Femoral) Interpectoral (PECS I) and pectoserratus (PECS II) Transversus abdominis plane (TAP) Serratus Plane (SP) Infra-inguinal Facia Iliaca (Infra-inguinal FI) Data will be collected in the form of scenes (target block view) and non-scenes (areas adjacent to the target block view).

Official Title
-----------------
ScanNav Anatomy PNB FDA Data Collection Plan

Conditions
-----------------
Ultrasound Recordings

Intervention / Treatment
-----------------
* Other: Ultrasound scans


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, at least 18 years of age; Able to comprehend and sign the Informed Consent prior to enrolment in the study. Exclusion Criteria: Aged <18 years of age; Unwilling or unable to provide informed consent. Previous history of medical interventions that may affect the anatomy of the chosen scan areas, e.g. hip replacements.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Volunteer Participants<br>Healthy adult (18+ years old) volunteers | Other: Ultrasound scans<br>* Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ultrasound scan recordings | Ultrasound scan recordings collected by experts in ultrasound-guided regional anaesthesia. | 6 months |
PheCheck Feasibility Study

Study Overview
=================
Brief Summary
-----------------
The goal of this feasibility study clinical trial is to compare the accuracy of PheCheck™ for the rapid quantitative detection of phenylalanine (Phe) with the gold standard (HPLC amino acid analyzer), in patients with PKU. The main aims are: Evaluate the accuracy of PheCheck as compared to the gold standard Evaluate ease of use by lay participants

Detailed Description
-----------------
The primary objective of this feasibility study is to evaluate the accuracy of the analyte concentration of PheCheck™ for the rapid, quantitative detection of phenylalanine (Phe) from capillary blood compared to the gold standard (HPLC amino acid analyzer) which quantitatively measures Phe in venous blood. The study will enroll subjects into one study cohort. It will include patients 10 years or older, monitored for Phenylketonuria (PKU), hyperphenylalaninemia or PKU during pregnancy.

Official Title
-----------------
PheCheck Feasibility Study

Conditions
-----------------
Phenylketonurias

Intervention / Treatment
-----------------
* Device: PheCheck™
* Diagnostic Test: HPLC Amino Acid Analyzer
* Diagnostic Test: Dried Blood Spot Cards


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 10 years of age or older Being monitored for Phenylketonuria (PKU), hyperphenylalaninemia or for PKU during pregnancy Signed informed consent Exclusion Criteria: Younger than 10 years of age Not being monitored for Phenylketonuria (PKU), hyperphenylalaninemia or for PKU during pregnancy Lack of signed informed consent Previous enrollment in the study and has completed study visit 1 and 2

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: PheCheck™|1 fingerstick specimen collected at each study visit|
|Diagnostic Test: HPLC Amino Acid Analyzer|1 venous specimen collected at each study visit|
|Diagnostic Test: Dried Blood Spot Cards|capillary blood specimen collected at each study visit|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of phenylalanine (Phe) from PheCheck as compared to HPLC amino acid analyzer | The primary outcome is the concentration of phenylalanine (Phe) from capillary blood as compared to the gold standard HPLC amino acid analyzer | 6-8 weeks |
First Rib Resection Versus Avulsion for Thoracic Outlet Syndrome

Study Overview
=================
Brief Summary
-----------------
The management of thoracic outlet syndrome can be either surgical or nonsurgical. Fewer than 20% of patients experience benefits from nonsurgical treatments. Regarding the surgical approach, there's considerable debate about whether to resect the first rib or if a scalenectomy alone suffices. Recently, many experts have concurred on the resection of the first rib. Based on our observations, avulsion of the first rib results in improved outcomes and reduced post-operative pain compared to simple resection. Thus, this study aims to compare the outcomes of first rib resection versus its avulsion in patients with thoracic outlet syndrome.

Official Title
-----------------
First Rib Resection Versus Avulsion for the Management of Thoracic Outlet Syndrome

Conditions
-----------------
Thoracic Outlet Syndrome

Intervention / Treatment
-----------------
* Procedure: first rib resection
* Procedure: First rib avulsion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any patient diagnosed as a case of neurogenic thoracic outlet syndrome - Exclusion Criteria: patients with other types of thoracic outlet syndrome (vascular TOS) -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Rib Resection Group<br>This arm undergoes first rib resection, as mentioned in the textbook. | Procedure: first rib resection<br>* standard first rib resection<br>* Other names: surgery;|
| Experimental: Rib Avulsion Group<br>This group of patients undergo first rib avulsion | Procedure: First rib avulsion<br>* As the active treatment, just instead of resectioning the first rib, we will do an avulsion of the first rib through the same incision<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient satisfaction | Numeric Rating Scale (NRS) is used to measure satisfaction, the patients are asked to rate their satisfaction on a scale from 0 to 10, with 0 representing completely dissatisfied and 10 representing completely satisfied. | six months | 
| post operative pain | we use the Visual Analogue Scale. A range of scores from 0-100. A higher score indicates greater pain intensity. the least value is zero and the highest value is 100 | four weeks after the operation |